10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

ATF2 Antibody (Center T339) Blocking Peptide

Synthetic peptide
Catalog # BP16866c

Specification

ATF2 Antibody (Center T339) Blocking Peptide - Product Information

Primary Accession P15336

ATF2 Antibody (Center T339) Blocking Peptide - Additional Information

Gene ID 1386

Other Names
Cyclic AMP-dependent transcription factor ATF-2, cAMP-dependent transcription factor ATF-2, Activating transcription factor 2, Cyclic AMP-responsive element-binding protein 2, CREB-2, cAMP-responsive element-binding protein 2, HB16, Histone acetyltransferase ATF2, cAMP response element-binding protein CRE-BP1, ATF2, CREB2, CREBP1

Format
Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions
This product is for research use only. Not for use in diagnostic or therapeutic procedures.

ATF2 Antibody (Center T339) Blocking Peptide - Protein Information

Name ATF2

Synonyms CREB2, CREBP1

Function
Transcriptional activator which regulates the transcription of various genes, including those involved in anti-apoptosis, cell growth, and DNA damage response. Dependent on its binding partner, binds to CRE (cAMP response element) consensus sequences (5'-TGACGTCA- 3') or to AP-1 (activator protein 1) consensus sequences (5'-TGACTCA- 3'). In the nucleus, contributes to global transcription and the DNA damage response, in addition to specific transcriptional activities that are related to cell development, proliferation and death. In the cytoplasm, interacts with and perturbs HK1- and VDAC1-containing complexes at the mitochondrial outer membrane, thereby impairing mitochondrial membrane potential, inducing mitochondrial leakage and promoting cell death. The phosphorylated form (mediated by ATM) plays a role in the DNA damage response and is involved in the ionizing radiation (IR)-induced S phase checkpoint control and in the recruitment of the MRN complex into the IR-induced foci (IRIF). Exhibits histone acetyltransferase (HAT) activity which specifically acetylates histones H2B and H4 in vitro (PubMed:10821277). In concert

with CUL3 and RBX1, promotes the degradation of KAT5 thereby attenuating its ability to acetylate and activate ATM. Can elicit oncogenic or tumor suppressor activities depending on the tissue or cell type.

Cellular Location
Nucleus. Cytoplasm. Mitochondrion outer membrane. Note=Shuttles between the cytoplasm and the nucleus and heterodimerization with JUN is essential for the nuclear localization Localization to the cytoplasm is observed under conditions of cellular stress and in disease states. Localizes at the mitochondrial outer membrane in response to genotoxic stress. Phosphorylation at Thr-52 is required for its nuclear localization and negatively regulates its mitochondrial localization. Co-localizes with the MRN complex in the IR-induced foci (IRIF)

Tissue Location
Ubiquitously expressed, with more abundant expression in the brain

ATF2 Antibody (Center T339) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Blocking Peptides

ATF2 Antibody (Center T339) Blocking Peptide - Images

ATF2 Antibody (Center T339) Blocking Peptide - Background

This gene encodes a transcription factor that is a memberof the leucine zipper family of DNA binding proteins. This proteinbinds to the cAMP-responsive element (CRE), an octamericpalindrome. The protein forms a homodimer or heterodimer with c-Junand stimulates CRE-dependent transcription. The protein is also ahistone acetyltransferase (HAT) that specifically acetylateshistones H2B and H4 in vitro; thus it may represent a class ofsequence-specific factors that activate transcription by directeffects on chromatin components. Additional transcript variantshave been identified but their biological validity has not beendetermined.

ATF2 Antibody (Center T339) Blocking Peptide - References

Bailey, S.D., et al. Diabetes Care 33(10):2250-2253(2010)Carrillo, R.J., et al. Biophys. Chem. 151(3):149-154(2010)Lee, S.H., et al. Oncogene 29(37):5182-5192(2010)Salameh, A., et al. J. Biol. Chem. 285(30):23096-23104(2010)Bolat, I., et al. Folia Histochem. Cytobiol. 48(2):197-201(2010)